Change 5-day change 1-year change 3-year change Capi.($)
+5.60%-6.13% - - 30Cr
+0.99%+0.35%+4.91%+16.06% 4.87TCr
+3.71%+6.75%+459.45%+557.32% 4.21TCr
+2.70%+0.38%+34.49%+10.04% 3.83TCr
+5.60%+8.13%+16.67%+72.18% 3.75TCr
+2.21%+4.89%+17.24%+51.64% 3.14TCr
+2.23%+1.73% - - 1.65TCr
+0.97%+2.14%+37.25%+128.28% 1.63TCr
-0.11%+1.75%+8.05%+18.47% 1.4TCr
+0.75%+14.01%+77.94%+29.28% 1.27TCr
Average +2.50%+3.06%+82.00%+110.41% 2.86TCr
Weighted average by Cap. +2.58%+2.31%+98.60%+131.40%
Logo OvaScience Inc
Tempest Therapeutics, Inc.(Tempest), formerly Millendo Therapeutics, Inc., is a clinical-stage oncology company. The Company is focused on developing therapeutics that combine both targeted and immune-mediated mechanisms to treat a wide range of tumors. The Company's two clinical programs are TPST-1495 and TPST-1120. The Company's both TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally-available inhibitor of TREX-1 designed to activate cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity.
Employees
-